Converting indoprofen to moderate selective COX-2 inhibitors: Design, synthesis and biological evaluation
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Huifang Lai und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Zhangzhou Health Vocational College, Zhangzhou 363000, Fujian Province, China. Hauptthemen laut MEDLINE: Drug Design, Anti-Inflammatory Agents, Non-Steroidal, Cyclooxygenase 2 Inhibitors, Cyclooxygenase 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, Empire State Development's Division of Science, Technology and Innovation.
Abstract (Originalsprache)
Moderate COX-2 inhibitors with favorable safety profiles might benefit the treatment of ulcerative colitis. Herein, biochemical differences between COX-1 and COX-2 enzymes were exploited to identify a strategy for converting the nonsteroidal anti-inflammatory drug indoprofen into moderately selective COX-2 inhibitors through the installation of amides (7a-7y) and sulfonamides (8a-8g) at its C-7 position. The cyclooxygenase inhibition assays dementated that compounds 7m, 7x, 7y, and 8d, displayed moderate selectivity towards the COX-2 enzyme (selectivity indexes = 10.57-18.35) compared with indoprofen (selectivity index = 0.78) and celecoxib (selectivity index = 57.47). 7y was also more effective in anti-inflammatory than celecoxib, observed by inhibiting NO, TNF-α, and IL-6 towards lipopolysaccharide-induced murine macrophages. An absorption, distribution, metabolism, and excretion study revealed that the compounds were promising new oral anti-ulcerative colitis agents. More importantly, 7y exhibited better gastric safety profiles than indoprofen in vivo. 7y also strongly protects against DSS-induced ulcerative colitis, evidenced by significantly mitigating histological damage. The study suggested that the structural modification at the C-7 position of indoprofen can reduce its COX-1 inhibition while converting it into a moderately selective COX-2 inhibitor; compound 7y represents a promising lead for treating ulcerative colitis with minimal gastrointestinal side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Zhangzhou Health Vocational College, Zhangzhou 363000, Fujian Province, China.
- Department of Orthopaedic Surgery, Zhangzhou Affiliated Hospital of Fujian medical University, Zhangzhou 363000, Fujian Province, China.
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China.
- School of Pharmacy, Zhangzhou Health Vocational College, Zhangzhou 363000, Fujian Province, China. Electronic address: wangxp@zzwzy.edu.cn.
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China. Electronic address: zhadj@fjmu.edu.cn.
Förderung
- Natural Science Foundation of Fujian Province
- Empire State Development's Division of Science, Technology and Innovation
Zitieren
APA
Lai, H., Liang, Y., Xu, J., Guo, L., Deng, C., Wang, X., & Zha, D. (2025). Converting indoprofen to moderate selective COX-2 inhibitors: Design, synthesis and biological evaluation. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108593
Vancouver
Lai H, Liang Y, Xu J, Guo L, Deng C, Wang X, et al. Converting indoprofen to moderate selective COX-2 inhibitors: Design, synthesis and biological evaluation. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108593
BibTeX
@article{Lai2025,
author = {Lai, Huifang and Liang, Yijie and Xu, Jiexin and Guo, Lijun and Deng, Chenlu and Wang, Xiaoping and Zha, Daijun},
title = {Converting indoprofen to moderate selective COX-2 inhibitors: Design, synthesis and biological evaluation},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108593}
}
EUVIMED